Antigen-specific tumor vaccines: Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy

Yifan Zhai, James C. Yang, Yutaka Kawakami, Paul Spiess, Samuel C. Wadsworth, Lisa M. Cardoza, Larry A. Couture, Alan E. Smith, Steven A. Rosenberg

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

The human melanoma tumor Ags, MART1 and gp100, are specifically recognized by HLA-A2-restricted CD8+ CTLs derived from melanoma patients and appear to be involved in tumor regression. In order to develop immunizing vectors for the treatment of patients with metastatic melanoma, replication-defective recombinant adenoviruses, Ad2CMV-MART1 and Ad2CMV-gp100, which encode these tumor Ags, have been generated. Infection of non-Ag expressing HLA-A2+ cell lines A375 and MDA-231 with the vectors resulted in recognition by Ag- specific CTLs as demonstrated by specific target cell lysis and release of cytokines, including IFN-γ, TNF-α, and granulocyte-macrophage-CSF. Sodium butyrate and TNF-α can further augment adenovirus-mediated transgene expression and increase recognition by specific CTLs. Although adenovirus- infected cells expressed the E3/19K protein at detectable levels, significant reduction of surface MHC class I expression was observed in only 3 of 10 tumor cell lines infected with either Ad2CMV-MART1 or Ad2CMV-gp100. Because of the suspected homology between the human MART1 and gp100 genes and their murine counterparts, we immunized C57BL/6 mice with these recombinant adenoviruses and demonstrated that immunization with Ad2CMV-gp100 could protect mice from murine melanoma B16 challenge administered intradermally. Depletion of CD8+ but not CD4+ T cells in vivo from Ad2CMV-gp100-vaccinated mice eliminated the protective effect. The anti-gp100 T cells induced by Ad2CMV-gp100 vaccination appeared to be responsible for the protection. Thus, these recombinant adenoviruses encoding tumor Ags may be useful as vaccines to induce specific T cell immunity for cancer therapy.

Original languageEnglish
Pages (from-to)700-710
Number of pages11
JournalJournal of Immunology
Volume156
Issue number2
Publication statusPublished - 1996 Jan 15
Externally publishedYes

Fingerprint

Cancer Vaccines
Adenoviridae
Antigens
HLA-A2 Antigen
Melanoma
Neoplasms
T-Lymphocytes
Therapeutics
Experimental Melanomas
Butyric Acid
Tumor Cell Line
Transgenes
Inbred C57BL Mouse
Granulocytes
Immunity
Immunization
Vaccination
Vaccines
Macrophages
Cytokines

ASJC Scopus subject areas

  • Immunology

Cite this

Zhai, Y., Yang, J. C., Kawakami, Y., Spiess, P., Wadsworth, S. C., Cardoza, L. M., ... Rosenberg, S. A. (1996). Antigen-specific tumor vaccines: Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. Journal of Immunology, 156(2), 700-710.

Antigen-specific tumor vaccines : Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. / Zhai, Yifan; Yang, James C.; Kawakami, Yutaka; Spiess, Paul; Wadsworth, Samuel C.; Cardoza, Lisa M.; Couture, Larry A.; Smith, Alan E.; Rosenberg, Steven A.

In: Journal of Immunology, Vol. 156, No. 2, 15.01.1996, p. 700-710.

Research output: Contribution to journalArticle

Zhai, Y, Yang, JC, Kawakami, Y, Spiess, P, Wadsworth, SC, Cardoza, LM, Couture, LA, Smith, AE & Rosenberg, SA 1996, 'Antigen-specific tumor vaccines: Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy', Journal of Immunology, vol. 156, no. 2, pp. 700-710.
Zhai, Yifan ; Yang, James C. ; Kawakami, Yutaka ; Spiess, Paul ; Wadsworth, Samuel C. ; Cardoza, Lisa M. ; Couture, Larry A. ; Smith, Alan E. ; Rosenberg, Steven A. / Antigen-specific tumor vaccines : Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. In: Journal of Immunology. 1996 ; Vol. 156, No. 2. pp. 700-710.
@article{72b92c3e11644326b4c1b50cdf368249,
title = "Antigen-specific tumor vaccines: Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy",
abstract = "The human melanoma tumor Ags, MART1 and gp100, are specifically recognized by HLA-A2-restricted CD8+ CTLs derived from melanoma patients and appear to be involved in tumor regression. In order to develop immunizing vectors for the treatment of patients with metastatic melanoma, replication-defective recombinant adenoviruses, Ad2CMV-MART1 and Ad2CMV-gp100, which encode these tumor Ags, have been generated. Infection of non-Ag expressing HLA-A2+ cell lines A375 and MDA-231 with the vectors resulted in recognition by Ag- specific CTLs as demonstrated by specific target cell lysis and release of cytokines, including IFN-γ, TNF-α, and granulocyte-macrophage-CSF. Sodium butyrate and TNF-α can further augment adenovirus-mediated transgene expression and increase recognition by specific CTLs. Although adenovirus- infected cells expressed the E3/19K protein at detectable levels, significant reduction of surface MHC class I expression was observed in only 3 of 10 tumor cell lines infected with either Ad2CMV-MART1 or Ad2CMV-gp100. Because of the suspected homology between the human MART1 and gp100 genes and their murine counterparts, we immunized C57BL/6 mice with these recombinant adenoviruses and demonstrated that immunization with Ad2CMV-gp100 could protect mice from murine melanoma B16 challenge administered intradermally. Depletion of CD8+ but not CD4+ T cells in vivo from Ad2CMV-gp100-vaccinated mice eliminated the protective effect. The anti-gp100 T cells induced by Ad2CMV-gp100 vaccination appeared to be responsible for the protection. Thus, these recombinant adenoviruses encoding tumor Ags may be useful as vaccines to induce specific T cell immunity for cancer therapy.",
author = "Yifan Zhai and Yang, {James C.} and Yutaka Kawakami and Paul Spiess and Wadsworth, {Samuel C.} and Cardoza, {Lisa M.} and Couture, {Larry A.} and Smith, {Alan E.} and Rosenberg, {Steven A.}",
year = "1996",
month = "1",
day = "15",
language = "English",
volume = "156",
pages = "700--710",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - Antigen-specific tumor vaccines

T2 - Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy

AU - Zhai, Yifan

AU - Yang, James C.

AU - Kawakami, Yutaka

AU - Spiess, Paul

AU - Wadsworth, Samuel C.

AU - Cardoza, Lisa M.

AU - Couture, Larry A.

AU - Smith, Alan E.

AU - Rosenberg, Steven A.

PY - 1996/1/15

Y1 - 1996/1/15

N2 - The human melanoma tumor Ags, MART1 and gp100, are specifically recognized by HLA-A2-restricted CD8+ CTLs derived from melanoma patients and appear to be involved in tumor regression. In order to develop immunizing vectors for the treatment of patients with metastatic melanoma, replication-defective recombinant adenoviruses, Ad2CMV-MART1 and Ad2CMV-gp100, which encode these tumor Ags, have been generated. Infection of non-Ag expressing HLA-A2+ cell lines A375 and MDA-231 with the vectors resulted in recognition by Ag- specific CTLs as demonstrated by specific target cell lysis and release of cytokines, including IFN-γ, TNF-α, and granulocyte-macrophage-CSF. Sodium butyrate and TNF-α can further augment adenovirus-mediated transgene expression and increase recognition by specific CTLs. Although adenovirus- infected cells expressed the E3/19K protein at detectable levels, significant reduction of surface MHC class I expression was observed in only 3 of 10 tumor cell lines infected with either Ad2CMV-MART1 or Ad2CMV-gp100. Because of the suspected homology between the human MART1 and gp100 genes and their murine counterparts, we immunized C57BL/6 mice with these recombinant adenoviruses and demonstrated that immunization with Ad2CMV-gp100 could protect mice from murine melanoma B16 challenge administered intradermally. Depletion of CD8+ but not CD4+ T cells in vivo from Ad2CMV-gp100-vaccinated mice eliminated the protective effect. The anti-gp100 T cells induced by Ad2CMV-gp100 vaccination appeared to be responsible for the protection. Thus, these recombinant adenoviruses encoding tumor Ags may be useful as vaccines to induce specific T cell immunity for cancer therapy.

AB - The human melanoma tumor Ags, MART1 and gp100, are specifically recognized by HLA-A2-restricted CD8+ CTLs derived from melanoma patients and appear to be involved in tumor regression. In order to develop immunizing vectors for the treatment of patients with metastatic melanoma, replication-defective recombinant adenoviruses, Ad2CMV-MART1 and Ad2CMV-gp100, which encode these tumor Ags, have been generated. Infection of non-Ag expressing HLA-A2+ cell lines A375 and MDA-231 with the vectors resulted in recognition by Ag- specific CTLs as demonstrated by specific target cell lysis and release of cytokines, including IFN-γ, TNF-α, and granulocyte-macrophage-CSF. Sodium butyrate and TNF-α can further augment adenovirus-mediated transgene expression and increase recognition by specific CTLs. Although adenovirus- infected cells expressed the E3/19K protein at detectable levels, significant reduction of surface MHC class I expression was observed in only 3 of 10 tumor cell lines infected with either Ad2CMV-MART1 or Ad2CMV-gp100. Because of the suspected homology between the human MART1 and gp100 genes and their murine counterparts, we immunized C57BL/6 mice with these recombinant adenoviruses and demonstrated that immunization with Ad2CMV-gp100 could protect mice from murine melanoma B16 challenge administered intradermally. Depletion of CD8+ but not CD4+ T cells in vivo from Ad2CMV-gp100-vaccinated mice eliminated the protective effect. The anti-gp100 T cells induced by Ad2CMV-gp100 vaccination appeared to be responsible for the protection. Thus, these recombinant adenoviruses encoding tumor Ags may be useful as vaccines to induce specific T cell immunity for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030026871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030026871&partnerID=8YFLogxK

M3 - Article

C2 - 8543823

AN - SCOPUS:0030026871

VL - 156

SP - 700

EP - 710

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -